AzurRx BioPharma EBIT

As of the most recent data (March 2026), AZRX shows a EBIT of $-9.9M. That compares with $-22M in the prior-year period — up 54.7% year over year. That is below the Healthcare sector average of $22B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AZRX's EBIT is now $-9.9M (was $-22M) — a 54.7% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether AzurRx BioPharma is outperforming or lagging.

The Healthcare sector average EBIT is about $22B. AzurRx BioPharma is at $-9.9M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how AZRX stacks up against individual peers as well.

Tracking AZRX's ebit over time shows whether AzurRx BioPharma is scaling, shrinking, or reshaping that part of the business. The current reading is $-9.9M That compares with $-22M in the prior-year period — up 54.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has AzurRx BioPharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-9.9M) with ownership activity and broader fundamentals.